**Specifications Table**TableSubject areaBiologyMore specific subject areaEndocrinology, BioinformaticsType of dataTables, FiguresHow data was acquiredDNA sequencing, Swiss-PDB viewer (3D structure), mutation severity prediction software'sData formatAnalyzedExperimental factorsDNA from blood of CAH patientsExperimental featuresBioinformatic toolsData source locationChandigarh, IndiaData accessibilityNA

**Value of the data**•The 3-Dimensional structure of the 21-Hydroxylase protein illustrates the site of the amino acid residues found to be mutated in cohort under study.•The data indicated the sequence of the primers constructed for the functional characterization of the mutations in 21-Hydroxylase deficient patients.•Bioinformatic analysis served as a pivotal tool in understanding functional consequences of the mutation\'s on the protein.

1. Data {#s0005}
=======

Congenital Adrenal Hyperplasia (CAH, OMIM \#201910) is an inborn error of metabolism which describes a group of autosomal recessive disorder, characterized by the enzyme defects in the steroidogenic pathway [@bib2]. Molecular analysis of CYP21A2 gene is of utmost importance to for the clinical diagnosis [@bib3]. Mutations were identified in CYP21A2 gene by SSCP and subsequent DNA sequencing [@bib1] ([Fig. 1](#f0005){ref-type="fig"}). Moreover, the functional characterization of the mutations is equally pivotal for diagnosis and subsequent genetic counseling. The sequence of the primers for the functional characterization of p.H365N, p.F306V and Double mutant (p.F306V, F306+T frameshift mutation) are listed in [Table 1](#t0005){ref-type="table"}. Additionally, bioinformatic analysis acts as a complement to the *in vitro* characterization. SIFT, PROVEAN and PolyPhen were used to predict the effect of mutations on the 21-Hydroxylase protein ([Table 2](#t0010){ref-type="table"}). The structure of the resultant mutant 21-Hydroxylase protein was analysed by HOPE (Have yOur Protein Explained) ([Table 3](#t0015){ref-type="table"}). Overall structure of the 3D model of CYP21A2 was constructed using Swiss-PDB viewer indicating helices, strands and coils in the protein structure. Also, indicating localization of heme, His365, Phe306 and Leu307 in the. protein ([Fig. 2](#f0010){ref-type="fig"}).Fig. 1Detection of novel mutations by SSCP and DNA sequencing. (A) SSCP analysis of exon 7. N- Control, P -CAH patient. Arrow indicates the deletion in band. (B) SSCP analysis of exon 8. C- Control, P -CAH patient. Arrow indicates the deletion in band. (C) CYP21A2 gene sequence showing the Wild type sequence, CYP21A2 gene showing substitution of T to G in a heterozygous state at position 916 in cDNA resulting in a missense mutation at codon 306. (D) CYP21A2 gene sequence showing the Wild type sequence, CYP21A2 gene showing substitution of C to A in a heterozygous state at position 1095 in cDNA resulting in a missense mutation at codon 365.Fig. 1Table 1List of primers used for the site directed mutagenesis.Table 1**p.F306V**F -- CCTCTCCTGGGCCGTGGTTgTTTTGCTTCACCACCR -- GGTGGTGAAGCAAAAcAACCACGGCCCAGGAGAGG**p.H365N**F -- CCTTAGCCTTGCCCaACCGCACCACACGGCCR -- GGCCGTGTGGTGCGGTtGGGCAAGGCTAAGG**Double mutant (p.F306V, F306+T frameshift mutation)**F -- CCTCTCCTGGGCCGTGGTTgTTTTtGCTTCACCACCR - GGTGGTGAAGCaAAAAcAACCACGGCCCAGGAGAGGTable 2List of the mutants and the in silico prediction of CYP21A2 mutations.Table 2Mutation/polymorphismCodon changePrediction phenotype (Score)SIFTPROVEANPolyPhen**F306V**TTT → GTTAffect protein function (0.01)Deleterious (− 50420)Probably damaging (0.996)**H365N**CAC → AACAffect protein function 0.01)Deleterious (− 6.415)Probably damaging (1.000)Table 3Severity prediction of the mutants by HOPE algorithm.Table 3Structure prediction by HOPE**F306V**Due to the smaller size of mutant amino acid in the protein as compared to wild-type, it caused an empty space in the core of the protein**H365N**Wild-type residue has interactions with ligand "heme". The difference in properties of mutant and wild-type easily caused loss of interaction with the ligand heme. The new mutant residue was too small to make the multimer contacts in the protein structure.Fig. 2Ribbon diagram of human P450c21 as generated by Swiss PDB viewer. (A) Overall structure of the 3D model of CYP21A2 indicating helices, strands and coils in the protein structure. (B) 3D model structure of CYP21A2 indicating localization of heme, His365, Phe306 and Leu307 in the structure.Fig. 2

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. SSCP: identification of mutations {#s0015}
--------------------------------------

All amplified exons of CYP21A2 gene were subjected to mutational analysis using SSCP as described by Sharma et al. [@bib4].

2.2. Severity prediction {#s0020}
------------------------

The output prediction score of the novel mutations was analyzed using software PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph>). Pathological predictions were further confirmed by another computer algorithm PROVEAN (<http://provean.jcvi.org/index.php>) and SIFT (<http://blocks.fhrc.org/sift/SIFT.html>). In addition, two polymorphisms were also analysed for the severity prediction so as to check the efficacy of the computational programs. Effect of mutations over CYP21A2 protein structure was determined using software have your protein explained (HOPE) available at web server (<https://www.cmbri.ru.nl/hope/>) [@bib5].

2.3. Homology modelling {#s0025}
-----------------------

Template model was human CYP21A2, previously generated as described by Robins et al. [@bib6] and available at Protein data Bank (PDB) with ID 2GEG. It was based on the X-ray crystallographic cytochrome CYP2C5 (PDB code 1N6B), which shares 32% sequence identity and 50% sequence similarity. We determined the protein helices, sheets and turns along heme binding region in protein.
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